Aripiprazole
- Generic Name
- Aripiprazole
- Brand Names
- Abilify, Aripiprazole Mylan Pharma (previously Aripiprazole Pharmathen), Abilify Maintena, Aripiprazole Accord, Aripiprazole Sandoz, Aripiprazole Zentiva
- Drug Type
- Small Molecule
- Chemical Formula
- C23H27Cl2N3O2
- CAS Number
- 129722-12-9
- Unique Ingredient Identifier
- 82VFR53I78
- Background
Aripiprazole is an atypical antipsychotic orally indicated for the treatment of schizophrenia, bipolar I, major depressive disorder, irritability associated with autism, and Tourette's. It is also indicated as an injection for agitation associated with schizophrenia or bipolar mania. Aripiprazole exerts its effects through agonism of dopaminergic and 5-HT1A receptors and antagonism of alpha-adrenergic and 5-HT2A receptors. Aripiprazole was given FDA approval on November 15, 2002.
- Indication
Aripiprazole is indicated for the treatment of acute manic and mixed episodes associated with bipolar I disorder, irritability associated with autism spectrum disorder, schizophrenia, and Tourette's disorder. It is also used as an adjunctive treatment of major depressive disorder.[L45859 An injectable formulation of aripiprazole is indicated for agitation associated with schizophrenia or bipolar mania. Finally, an extended-release, bimonthly injection formulation of aripiprazole is indicated for the treatment of adult schizophrenia and maintenance therapy for adult bipolar I disorder.
- Associated Conditions
- Agitation, Bipolar 1 Disorder, Irritability, Major Depressive Disorder (MDD), Mixed manic depressive episode, Psychosis, Psychotic Depression, Schizophrenia, Tourette's Disorder (TD), Acute Manic episode
- Associated Therapies
- Monotherapy
Biomarkers to Enhance Early Schizophrenia Treatment
- Conditions
- Schizophenia Disorder
- Interventions
- First Posted Date
- 2025-05-14
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- Northwell Health
- Target Recruit Count
- 180
- Registration Number
- NCT06969755
- Locations
- 🇺🇸
Feinstein Institute for Medical Research, Glen Oaks, New York, United States
Neurobiological Mechanisms of Pathological Rumination and Effects of Aripiprazole
- Conditions
- Major Depressive Disorder (MDD)Rumination
- Interventions
- First Posted Date
- 2025-04-22
- Last Posted Date
- 2025-04-22
- Lead Sponsor
- Not specified
- Target Recruit Count
- 60
- Registration Number
- NCT06937476
A Double-Blind, Randomized Comparative Study of Carliprazine and Aripiprazole in Patients with Acute Schizophrenia
- Conditions
- Acute Schizophrenia
- Interventions
- Drug: Hydrochloride Carliprazine capsules
- First Posted Date
- 2024-09-10
- Last Posted Date
- 2024-09-10
- Lead Sponsor
- Chengdu Kanghong Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 376
- Registration Number
- NCT06589817
Maintenance Electroconvulsive Therapy (ECT) Versus Aripiprazole in Clozapine-resistant Schizophrenia
- Conditions
- Clozapine Resistant Schizophrenia
- Interventions
- Procedure: maintenance ECT
- First Posted Date
- 2024-07-15
- Last Posted Date
- 2024-07-16
- Lead Sponsor
- All India Institute of Medical Sciences, Bhubaneswar
- Target Recruit Count
- 40
- Registration Number
- NCT06501339
A Trial to Assess a Wearable Patch's Functioning to Detect Medication Ingestion
- Conditions
- Mental DisorderSchizophreniaMajor Depressive DisorderBipolar I Disorder
- Interventions
- First Posted Date
- 2024-04-17
- Last Posted Date
- 2024-07-31
- Target Recruit Count
- 54
- Registration Number
- NCT06372210
- Locations
- 🇺🇸
Research site, Garden Grove, California, United States
Atypical Antipsychotic-induced Mitochondrial Dysfunction in Patients With Schizophrenia
- First Posted Date
- 2024-02-01
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- All India Institute of Medical Sciences, Bhubaneswar
- Target Recruit Count
- 60
- Registration Number
- NCT06236451
- Locations
- 🇮🇳
All India Institute of Medical Sciences (AIIMS), Bhubaneswar, Odisha, India
The Characteristics of Treatment Resistant Schizophrenia From the Illness Onset
- Conditions
- Treatment-resistant Schizophrenia
- Interventions
- First Posted Date
- 2023-11-13
- Last Posted Date
- 2023-11-13
- Lead Sponsor
- Peking University
- Target Recruit Count
- 300
- Registration Number
- NCT06128408
Multidisciplinary Design to Optimize Schizophrenia Treatment Based on Multi-omics Data and Systems Biology Analysis
- Conditions
- DiabetesPsychosisSchizophreniaTreatment-resistant SchizophreniaSide EffectLipid Metabolism DisordersNAFLD
- Interventions
- First Posted Date
- 2023-09-29
- Last Posted Date
- 2023-09-29
- Lead Sponsor
- Consorcio Centro de Investigación Biomédica en Red (CIBER)
- Target Recruit Count
- 244
- Registration Number
- NCT06060886
EFFECT OF RISPERIDONE vs ARIPIPRAZOLE ON OXIDATIVE STRESS IN PATIENTS WITH AUTISM SPECTRUM DISORDER: A RANDOMIZED CONTROLLED TRIAL
- Conditions
- The Goal of This Trial is to to Compare the Effect of Risperidone vs Aripiprazole in Terms of Change in Serum Glutathione Level
- Interventions
- First Posted Date
- 2023-05-22
- Last Posted Date
- 2023-05-22
- Lead Sponsor
- All India Institute of Medical Sciences, Bhubaneswar
- Target Recruit Count
- 42
- Registration Number
- NCT05868720
Sequenced Treatment Alternatives to Relieve Adolescent Depression (STAR-AD)
- Conditions
- SequestraDepression
- Interventions
- First Posted Date
- 2023-04-18
- Last Posted Date
- 2023-08-14
- Lead Sponsor
- First Affiliated Hospital of Chongqing Medical University
- Target Recruit Count
- 520
- Registration Number
- NCT05814640
- Locations
- 🇨🇳
The First Affiliated Hospital of Chongqing Medical University, Chongqing, Province, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.